Fig. 2From: PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathwayOverexpressed PAK4 ameliorates the cisplatin-induced viability reduction of cervical cancer cells. a and b: The percent viability of Hela (a) and CaSki (b) cells which were transfected with control pcDNA3.1 (pcDNA3.1-Con) or pcDNA3.1-PAK4, with or without the treatment with 5 μM (for Hela cells) or 10 μM (for CaSki cells) cisplatin for 24 h; c and d: Time-dependence of the influence of the transfection with pcDNA3.1-Con or with pcDNA3.1-PAK4 on the viability of Hela (c) and CaSki (d) cells, in the presence of 5 μM (for Hela cells) or 10 μM (for CaSki cells) cisplatin. All results were averaged for triple independent experiments. *P < 0.05, **P < 0.01 or ns: no significanceBack to article page